NASDAQ: NRSN
Neurosense Therapeutics Ltd Stock Ownership - Who owns Neurosense Therapeutics?

Insider buying vs selling

Have Neurosense Therapeutics Ltd insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when NRSN insiders and whales buy or sell their stock.

NRSN Shareholders

What type of owners hold Neurosense Therapeutics Ltd stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Morgan Stanley0.22%50,501$96.46kInstitution
Meitav Investment House Ltd 10.17%40,000$76.40kInstitution
Xtx Topco Ltd0.15%33,706$64.38kInstitution
Commonwealth Equity Services LLC0.07%17,250$32.95kInstitution
Geode Capital Management LLC0.07%15,870$30.31kInstitution
Two Sigma Securities LLC0.06%14,705$28.09kInstitution
Warberg Asset Management LLC0.05%10,700$20.44kInstitution
Hurley Capital LLC0.04%8,710$16.64kInstitution
Ubs Group Ag0.01%2,275$4.35kInstitution
Cwm LLC0.00%1,000$1.91kInstitution

1 of 2

NRSN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
NRSN0.84%0.00%
MURA48.61%3.39%Net Selling
ATHE0.00%0.00%
PRLD48.16%51.84%Net Buying
ATNM20.92%79.08%

Neurosense Therapeutics Stock Ownership FAQ

Who owns Neurosense Therapeutics?

Neurosense Therapeutics (NASDAQ: NRSN) is owned by 0.84% institutional shareholders, 0.00% Neurosense Therapeutics insiders, and 99.16% retail investors. Morgan Stanley is the largest individual Neurosense Therapeutics shareholder, owning 50,501.00 shares representing 0.22% of the company. Morgan Stanley's Neurosense Therapeutics shares are currently valued at $96.46k.

If you're new to stock investing, here's how to buy Neurosense Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.